Shares of this under-the-radar weight-loss drug play could double, says Leerink Partners
|
| Post date: 2025-09-10 03:47:54 |
| Views: 7 |
| The investment firm initiated coverage of the biopharma stock at a outperform rating. |
| Please click Here to read the full story. |
| |
| Other Top and Latest Questions: |
Gold is on a record run — here's how to invest, according to experts
|
The White House is exploring how to keep Trump's tariffs if the Supreme Court strikes them down
|
Nvidia's breakdown, dismal jobs report and other ills fail to slow down this bull market by much yet
|
OpenAI expects business to burn $115 billion through 2029, The Information reports
|
DOJ says names of two associates Epstein wired $100k and $250k to should stay secret
|
Stocks making the biggest moves midday: UnitedHealth, Kingsoft Cloud, Brighthouse Financial & more
|
Fewer people think retirement will 'take a miracle,' report finds. But inflation worries persist
|
Shares of this under-the-radar weight-loss drug play could double, says Leerink Partners
|
White House says jobs revision proves Biden economy a 'disaster,' BLS is 'broken,' Powell was 'too late'
|
JPMorgan CEO Jamie Dimon says the economy 'is weakening'
|
Video
Web
Image
Music
BlogU
